Product Description
FLX475 is a small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues, without depleting Treg throughout the body. (Sourced from: https://rapt.com/pipeline/flx475/#:~:text=FLX475%20is%20a%20small%20molecule,the%20likelihood%20of%20side%20effects.)
Mechanisms of Action: CCR4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: RAPT Therapeutics
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Brian Wong
Additional Commercial Interests: Hanmi
Clinical Description
Countries in Clinic: Australia, Hong Kong, Korea, Taiwan, Thailand, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Breast Cancer|Cervical Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Lymphoma|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FLX475-02 | P2 |
Completed |
Head and Neck Cancer|Lymphoma|Breast Cancer|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Transitional Cell Carcinoma|Nasopharyngeal Cancer|Cervical Cancer |
2024-12-31 |
|
| HM-CCRI-201 | P2 |
Completed |
Gastrointestinal Cancer |
2024-08-12 |